This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients who do not have the Duffy null phenotype and receive the same standard of care regimens to see if there are differences in dose modifications and neutropenic fever between the two groups. The survey studies seek to understand general health experiences and preferences and experiences specific to people with Duffy null phenotype.
Study Drugs Include:
* Daratumumab * lenalidomide * bortezomib * dexamethasone * carboplatin * paclitaxel * pembrolizumab * cyclophosphamide * doxorubicin
Cohort 1: MM, based on IMWG criteria12, and currently requires treatment
Cohort 2: Stage II or III TNBC, with definition per protocol Section 3.2.1 AND
Cohort 1: Dara-RVd for MM
Cohort 2: A Keynote 522-based regimen of carboplatin, paclitaxel, and pembrolizumab given as the first phase of neoadjuvant treatment for TNBC.***
Inability to understand and the willingness to sign a written informed consent document
ANC<500 within 7 days of planned start of Cycle 1 Day 1.
Participants who have started treatment at the time of enrollment cannot have started Cycle 2 of therapy
Participants in Cohort 2 (TNBC) cannot have received any of the pembrolizumab, doxorubicin, and cyclophosphamide portion of therapy
Andrew Hantel, MD
Lead sponsor
Dana-Farber Cancer Institute
Sponsor institution